Welcome to our dedicated page for INVESTMENT MANAGERS SER TR II news (Ticker: SNPX), a resource for investors and traders seeking the latest updates and insights on INVESTMENT MANAGERS SER TR II stock.
TAO Synergies Inc., formerly Synaptogenix, reports developments tied to its Nasdaq-listed common stock, corporate rebranding, and digital asset treasury strategy centered on TAO, the native cryptocurrency of the Bittensor network. Recurring updates include TAO acquisitions, staking activity, custody and trading arrangements, ticker-symbol changes, shareholder voting matters, governance actions, and capital-structure disclosures.
The company’s historical Synaptogenix news also covers clinical-stage biopharmaceutical work in neurodegenerative disorders through Bryostatin-1 and polyunsaturated fatty acid analogs, including FDA-authorized IND activity, orphan-drug designation for Fragile X syndrome, patent matters, and research collaborations.
Synaptogenix, Inc. (OTC: SNPX) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled virtually for March 9-10, 2021. The presentation will feature CEO Alan Tuchman M.D. and President Daniel Alkon M.D., available on-demand starting at 7 a.m. EST on March 9. Synaptogenix focuses on developing therapies for neurodegenerative diseases, with its lead candidate, Bryostatin-1, showing promise in treating Alzheimer's and other conditions. The company has received Orphan Drug Designation from the FDA for Bryostatin-1 for Fragile X syndrome.
Synaptogenix (OTC: SNPX), a biopharmaceutical firm, announced its participation in two scientific conferences. On February 25, Dr. Daniel Alkon will present a virtual poster at the Neurodegenerative Drug Development Summit. On March 14, he will discuss findings from a pilot Phase II trial regarding Bryostatin-1's effects on Alzheimer's patients at the AD/PD 2021 conference. The trial revealed a significant improvement in Severe Impairment Battery scores. CEO Alan Tuchman expressed enthusiasm for sharing updates on ongoing trials and the development of Bryostatin-1.
Synaptogenix, Inc. (OTC: SNPX) announced participation in two scientific conferences on February 25 and March 14, focusing on neurodegenerative diseases. Dr. Daniel Alkon will present virtually at the 9th Annual Neurodegenerative Drug Development Summit and share findings from a pilot Phase 2 trial of Bryostatin-1 for Alzheimer's disease. The trial showed a significant improvement in cognitive scores. CEO Alan Tuchman expressed excitement for future updates on their ongoing studies.
Synaptogenix, Inc. (OTC: SNPX) announced its participation in the Winter Wonderland Conference from February 16-19, 2021. Dr. Alan Tuchman, CEO, and Dr. Daniel Alkon, CSO, will present on February 17 at 11:30 am EDT and hold one-on-one meetings on February 18 and 19. The conference, featuring curated presentations, aims to connect emerging biopharmaceutical opportunities with institutional investors. Synaptogenix focuses on developing neuro-regenerative therapies, especially Bryostatin-1 for Alzheimer's and other rare diseases, with FDA Orphan Drug Designation for Fragile X syndrome.
Synaptogenix, Inc. (OTC: SNPX), a biopharmaceutical firm focused on neurodegenerative therapies, has applied to list its common shares on the Nasdaq Stock Market. While the company believes it meets all listing requirements, approval is not guaranteed. CEO Dr. Alan J. Tuchman highlighted that Synaptogenix is well funded for its Phase 2 clinical trial of Bryostatin-1, its lead candidate for Alzheimer's treatment. The drug has received Orphan Drug Designation for Fragile X syndrome and has been tested on over 1,500 individuals, providing a substantial safety database.
Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first batch of synthetic Bryostatin under an exclusive licensing agreement with Stanford University. This development will enable the company to expand its research and conduct trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's disease. The synthetic supply addresses the need for increased availability, crucial for the development of orally deliverable compounds. The company aims to complement ongoing Phase 2 trials in Alzheimer's Disease with additional studies utilizing the new supply.
Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first synthetic Bryostatin batch, obtained through an exclusive licensing agreement with Stanford University. This development marks a significant milestone, allowing the company to expand its research initiatives, particularly for an orally deliverable compound. The increased supply will facilitate new clinical trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's. Synaptogenix's existing studies include Bryostatin-1, which has a notable safety profile from prior cancer research.